A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
收藏DataCite Commons2025-12-03 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012006/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
提供机构：
Vivli
创建时间：
2025-12-02
